Scarica l'app Stockscreener
1.31
3.68%
-0.05
Dopo l'orario di chiusura:
1.33
0.02
+1.53%
Precedente Chiudi:
$1.36
Aprire:
$1.36
Volume 24 ore:
105.89K
Relative Volume:
0.50
Capitalizzazione di mercato:
$74.15M
Reddito:
-
Utile/perdita netta:
$-131.52M
Rapporto P/E:
-0.736
EPS:
-1.78
Flusso di cassa netto:
$-107.56M
1 W Prestazione:
-6.43%
1M Prestazione:
+12.93%
6M Prestazione:
+70.13%
1 anno Prestazione:
-32.47%
Intervallo 1D:
$1.27
$1.4181
Intervallo di 1 settimana:
$1.15
$1.4181
Portata 52W:
$0.6101
$1.96
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Nome
Prelude Therapeutics Inc
Settore
Industria
Telefono
(302) 467-1280
Indirizzo
175 INNOVATION BOULEVARD, WILMINGTON
Confronta PRLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
1.31 | 73.58M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-03-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | Iniziato | Jefferies | Buy |
| 2022-03-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-02-28 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-10-08 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-04-26 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-09 | Iniziato | Barclays | Overweight |
| 2020-11-20 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Goldman | Neutral |
| 2020-10-20 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prelude Therapeutics Inc Borsa (PRLD) Ultime notizie
Can Prelude Therapeutics Incorporated stock sustain free cash flow growth2025 Trading Recap & AI Forecasted Entry/Exit Points - newser.com
Is Prelude Therapeutics Incorporated stock a defensive play in 20252025 Institutional Moves & Weekly Setup with High ROI Potential - newser.com
Can Prelude Therapeutics Incorporated stock maintain operating marginsCPI Data & Expert Approved Momentum Ideas - newser.com
How Prelude Therapeutics Incorporated stock reacts to oil pricesWeekly Trade Recap & Fast Entry High Yield Tips - newser.com
How moving averages guide Prelude Therapeutics Incorporated tradingJuly 2025 Patterns & Community Consensus Trade Alerts - newser.com
Is Prelude Therapeutics Incorporated stock supported by innovation pipelineEarnings Performance Report & Reliable Breakout Forecasts - newser.com
Using Bollinger Bands to evaluate Prelude Therapeutics IncorporatedCEO Change & AI Forecasted Entry/Exit Points - newser.com
Will Prelude Therapeutics Incorporated stock deliver shareholder value2025 Price Targets & High Return Stock Watch Alerts - newser.com
Published on: 2025-10-09 05:09:32 - newser.com
Can momentum traders help lift Prelude Therapeutics IncorporatedEarnings Summary Report & AI Driven Price Predictions - newser.com
Using economic indicators to assess Prelude Therapeutics Incorporated potentialFed Meeting & Safe Capital Allocation Plans - newser.com
Published on: 2025-10-09 02:10:25 - newser.com
Analyzing Prelude Therapeutics Incorporated with risk reward ratio charts2025 Big Picture & Free Safe Capital Growth Stock Tips - newser.com
CDK4/6 Inhibitor Market Positioned for Remarkable Growth as Revolutionary Therapies Transform Cancer Treatment Landscape in 2024 - Barchart.com
Full technical analysis of Prelude Therapeutics Incorporated stock2025 Bull vs Bear & Daily Growth Stock Investment Tips - newser.com
Will Prelude Therapeutics Incorporated rebound enough to break evenEarnings Risk Report & Fast Momentum Entry Tips - newser.com
Multi asset correlation models including Prelude Therapeutics IncorporatedInsider Buying & Weekly Watchlist for Consistent Profits - newser.com
Will earnings trigger a reversal in Prelude Therapeutics IncorporatedPortfolio Return Summary & Verified Swing Trading Watchlists - newser.com
What drives Prelude Therapeutics Incorporated stock priceSector-Based Investing & Double Digit Trading Ideas - earlytimes.in
Contrasting Cardiol Therapeutics (NASDAQ:CRDL) & Prelude Therapeutics (NASDAQ:PRLD) - Defense World
Prelude Therapeutics (NASDAQ:PRLD) versus Talphera (NASDAQ:TLPH) Financial Contrast - Defense World
3 Promising Penny Stocks With Over $60M Market Cap - simplywall.st
Brokers Set Expectations for PRLD Q3 Earnings - Defense World
Prelude Therapeutics’ (PRLD) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright reiterates Buy rating on Prelude Therapeutics stock with $5 target - Investing.com Canada
Prelude Therapeutics (NASDAQ:PRLD) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates Buy Rating for PRLD, Price Target at $5.00 | PRLD Stock News - GuruFocus
New PROTACs revealed in Prelude Therapeutics patent - BioWorld MedTech
Prelude Therapeutics Inc Azioni (PRLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Prelude Therapeutics Inc Azioni (PRLD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
| Vaddi Krishna | CEO |
Dec 31 '24 |
Buy |
1.21 |
5,000 |
6,044 |
142,553 |
| Vaddi Krishna | CEO |
Dec 30 '24 |
Buy |
1.20 |
10,000 |
12,000 |
137,553 |
| Combs Andrew | Chief Chemistry Officer |
Dec 23 '24 |
Buy |
1.37 |
60,000 |
82,002 |
377,623 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):